Alyeska Investment Group
HRMY icon

Alyeska Investment Group’s Harmony Biosciences HRMY Stock Holding History

Alyeska Investment Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$1.81M – 773
2020
Q4 		$1.81M Buy
+50,000
New +$2.02M 0.03% 380

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Alyeska Investment Group's HRMY Position: Q1 2021 in Review

Alyeska Investment Group sold out of Harmony Biosciences (HRMY) in Q1 2021, closing a stake of 50,000 shares — an estimated $1.81M sold.

Alyeska Investment Group first reported a position in HRMY in Q4 2020 and held it in 1 quarter. The position peaked at $1.81M in Q4 2020. 57 funds tracked by Wall St. Rank hold HRMY as of Q1 2021.

  • Alyeska Investment Group reported no remaining Harmony Biosciences position as of Q1 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 Harmony Biosciences shares in Q1 2021, an estimated $1.81M.
  • Alyeska Investment Group first reported a position in Harmony Biosciences in Q4 2020 and held it in 1 quarter.
  • Alyeska Investment Group's Harmony Biosciences position peaked at $1.81M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2021.

Based on Alyeska Investment Group's 13F filing for Q1 2021, filed 17 May 2021.